The ability of ion permeability-inducing agents (ionophores) to complex and transport cations and amines across membranes has provided a novel approach for the pharmacological modification of biological systems. Of particular interest is X-537A, since it not only transports alkali ions but compared to most of the known ionophores it is unusually efficient in transporting calcium as well as catecholamines. The cardiovascular effects of this agent were studied in normal anesthetized dogs. X-537A produced a dramatic augmentation of myocardial contractility with up to 210% increases in max dP/dt after intravenous doses of 1.0-1.5 mg/kg. The moderate dose of 0.5-0.75 mg/kg X-537A induced significant increases in max dP/dt (68%, P < .001), isometric ventricular segmental tension (IVST) (79%, P < .01), peak dT/dt (65%, P < .05), cardiac output (44%, P < .001), aortic systolic (18%, P < .001) and diastolic (15%, P < .001) pressures, pulse pressure (28%, P < .001), left ventricular systolic pressure (18%, P < .001), and decrease in total peripheral resistance (23%, P < .05) without significant changes in heart rate and atrioventricular conduction. Beta-blockade with large doses of propranolol showed 20% suppression of the cardiac inotropism of X-537A. The action of X-537A is typically rapid with a smooth continuous progression until maximal response is attained in 10-15 minutes, sustained for about one hour, then gradually subsides during the third hour. Such ideal cardiovascular effects of X-537A portend a profound therapeutic potential in cases of cardiac decompensation and circulatory compromise. X-537A may also prove to be a valuable tool for probing the complex factors influencing myocardial contractility.
Myocardial contractility
Excitation-contraction coupling THE ABILITY OF IONOPHORES to mediate transmembrane cation transport was first reported by Pressman in 1964 in connection with studies of the bioenergetic properties of mitochondria.1 2 These compounds, which are for the most part microbial metabolites, form lipid soluble complexes with alkali and other cations. The complexation reaction is dynamically reversible which enables such agents to carry cations across the lipid barriers of bulk phase model systems as well as biological membranes, hence the generic term "ionophore," i.e., ion bearer.3 A general description of the structures and properties of ionophores is contained in a recent review. 4 When ionophores are added to biological membranes they concentrate within the lipid regions where they form lipid soluble cations complexes. The ability of ionophore-cation complexes to diffuse across biological membranes, taken together with the dynamic reversibility of complexation at membrane interfaces, enables ionophores to behave as extremely efficient mobile cation carriers within biological membranes. Most ionophores exhibit a remarkable capacity for ion discrimination, i.e., valinomycin shows 10,000:1 preference for K+ ion over Na+ ion for both complexation and transport.3 4 While most of the ionophores studied earlier selectively complex alkali cations, X-537A (3-methyl-6-{7-ethyl-4-hydroxy-3, 5dimethyl -6 -oxo -7 -[5-ethyl-3-methyl-5-(5-ethyl-5-hydroxy -6 -methyl -2 -tetrahydropyranyl)-2tetrahydrofuryl]heptyllsalicylic acid), the smallest of the known naturally occurring carboxylic ionophores, was particularly interesting because of its broad cation complexing spectrum.'5 6 X-537A (Hoffmann-LaRoche designation RO 2-2985) occurs as a metabolite of an unidentified streptomyces strain isolated from soil.7
The monovalent complexing affinity series of X-537A measured in a single phase of ethanol is Cs -Rb _ K > Na >> Li, while the divalent series is Ba > Mn > Mg > Sr > Ca, and in the biogenic amine series is dopamine > seratonin > ethanolamine Circulationi. V)olumnie XLIX, June 1974 > norepinephrine > epinephrine > isoproterenol. 8 While complexation is a requisite for ionophore mediated cation transport, the two processes are not necessarily proportionately related4 and thus in model systems calcium exhibits the highest transport turnover rates we have observed.8 Although X-537A is capable of complexing and transporting virtually all cations, the ones of principal concern in biological systems are Na+, K+, Ca++, Mg++ and the biogenic amines.
The capability of ionophores to induce selective membrane permeability to various ions active in biological control suggested a novel approach for the rational pharmacological control of biological systems. The role of Ca++ and catecholamines in the regulation of the cardiovascular system, as in cardiac and smooth muscle contraction, is well established. The ability of X-537A to increase isometric ventricular tension and the sinus rate in the artificially perfused, isolated, spontaneously beating guinea pig and rabbit heart has already been reported by our laboratory.5' 6, 8 Our discovery of the positive inotropic effects of X-537A has since been confirmed in other laboratories.9 10 The present paper extends these findings to the effects of X-537A on the cardiovascular system of anesthetized dogs.
Methods and Materials
Normal female mongrel dogs, weighing 30-35 lbs, were anesthetized with intravenous sodium pentobarbital 20 mg/kg. The animals were respired artifically with room air through an endotracheal tube. The rate and volume of respiration were adjusted according to the weight of the animals such that arterial blood pH and gases were maintained in the normal range.
Appropriate catheters were introduced through the femoral vessels to the left ventricular cavity, thoracic aorta and inferior vena cava for left ventricular and aortic pressure determinations, and drug administration, respectively. A bipolar catheter was positioned towards the medial cusp of the tricuspid valve for recording the His bundle electrogram. The derivative of the left ventricular pressure, LV dP/dt, was obtained separately from a Statham micromanometer-tipped catheter connected to an appropriate R-C differentiating circuit. A Walton-Brodie strain gauge was sutured at the mid-portion of the left ventricular myocardium for recording the isometric ventricular segmental tension (IVST). The derivative of this function, dT/dt, was obtained by an R-C differentiator and also recorded. Cardiac output was measured by the conventional dye dilution technique. Standard six limb-lead electrocardiograms were also recorded. All parameters were recorded simultaneously and continuously by a multichannel oscillographic recorder.
A water soluble form of X-537A was prepared by dissolving 20 mg/ml of the ionophore in ethanol and diluting with ten volumes of 2% bovine serum albumin. The resulting solution was frozen, lyophilized and the residue stored at room temperature. The desired quantity of the lyophilized Circulation, Volume XLIX, June 1974 X-537A-albumin was dissolved immediately before use in 5 ml bacteriostatic water and administered intravenously. During the earlier phases of the study, X-537A dissolved in dimethyl sulfoxide, 20 mg/ml was administered in a volume not exceeding 2 ml. No significant effects were observed with control injections of this solvent.
Dose-Response Relationship
Fourteen variable doses of X-537A, ranging from .03 to 3.0 mg/kg were injected intravenously in 7 dogs. ECG, aortic and left ventricular pressures, dP/dt, IVST and dT/dt were monitored continuously, before and after each dose of X-537A for up to three to four hours.
Cardiovascular Effects of Moderate Doses of X-537A
The dose of X-537A (0.5-0.75 mg/kg), which was previously determined not to produce significant changes in sinus rate, was administered intravenously in ten dogs. The effects on heart rate (HR), A-V nodal conduction (A-H) and His-Purkinje-ventricular conduction (H-V interval and QRS duration), aortic systolic (ASP) and diastolic (ADP) pressures, left ventricular systolic (LVSP) and end diastolic (LVEDP) pressures, maximum dP/dt, cardiac output (CO) and stroke volume (SV), and total peripheral resistance (TPR) were determined before and after drug injection. Similar procedures were done in another group of five dogs pretreated with a 2 mg/kg intravenous dose of propranolol, and paced at a constant rate of 110 beats/min.
Results
In dogs anesthetized with pentobarbital, which underwent thoracotomy, X-537A produced profound cardiovascular effects. The most striking response was the dose-related increase in myocardial contractility as measured by LV max dP/dt. Figure 1 shows the log dose-response curve of the dog myocardium to X-537A. The percentage increase in maximum LV dP/dt Il.i
Relationship between the increasing doses of X-537A injected intravenously (abscissa) and the percent increase in myocardial contractility, as determined from maximum dP/dt (ordinate). MD50 is the intravenous dosage of X-537A capable of producing 50% of maximum response.
was plotted logarithmically against the increasing doses of intravenously injected X-537A. Maximum responses as large as a 210% increase above the control have been observed at a dose of 1.5 mg/kg. The minimum effective dose (>10% increase in maximum LV dP/dt) is 0.1 mg/kg. MD50 is 0.75 mg/kg. The dose-response curve exhibits the sigmoid configuration usually obtained with pharmacologically active agent. Heart rate showed no significant change at doses of 0.1-1.0 mg/kg. Modest increases in heart rate of up to 20 beats/min occurred at higher doses of 1.25-2.0 mg/kg. At doses greater than 2 mg/kg (2.5-3.0 mg/kg), premature ventricular contractions (PVCs) occurred with either constant or variable coupling intervals; in some cases PVCs occurred in series. The PVCs were abolished or prevented with intravenous xylocaine, procaine amide, propranolol and much less efficiently with potassium chloride infusion. Untreated PVCs spontaneously disappeared after approximately an hour. Brady-tachyarrhythmia was observed in few instances at doses of 3 mg/kg. No changes were observed in the QRS and ST-T segments at doses up to 2.0 mg/kg. However, ST-T segment elevations of more than 1 mm were readily seen at doses greater than 2 mg/kg associated with the increase in heart rate.
Doses in the range of 0.5-0.75 mg/kg showed 60-105% increases in maximum LV dP/dt without significantly affecting heart rate. Subsequently this dose range was evaluated in 10 dogs with multiple hemodynamic parameters including a standard sixlead electrocardiogram and His bundle recordings. Table 1 summarizes the effects of this dose range of X-537A.
No significant changes were noted in the sinus rate, A-H, H-V and QRS time intervals. The ECG showed no changes in the arterial depolarization (P wave) and ventricular (QRS and ST-T wave) depolarization and repolarization processes. Parallel increases in maximum LV dP/dt, dT/dt and IVST are indicative of appreciable increases in myocardial contractility. The hemodynamic consequences of increased cardiac contractility with subjects in a normal circulatory state are generally not translated into an increase in cardiac output as has been repeatedly shown with digitalis in normal man", 12 and dogs.13 The increase in cardiac output and stroke volume observed in the present study could be a consequence of the circulation of the animals being compromised prior to X-537A administration as has been reported in pentobarbitaltreated dogs.'4 '5 This was supported by the rather borderline elevated values for left ventricular end diastolic pressure (mean = 8.8 ± 1.5 mm Hg) and markedly elevated total peripheral resistance (mean = 4650 ± 300 dynes sec/cm5) during the control period. The marked decrease in total peripheral resistance after X-537A appeared to contribute further to the increase in cardiac output and stroke volume.
Aortic pressure increased, although much less impressively than flow. While mean aortic pressure increased, the total peripheral resistance decreased. This suggests a differential action of X-537A on various regional vascular beds. The wider pulse pressure after X-537A reflects the increase in stroke volume. able 1 Cardiovascular Effects of X-537A Injected Intravenously at 0.5-0.75 mg/kg Dose Range 
537A. Isometric ventricular segmental tension (IVST)
ancl its derivative (dT/dt) increased to double the control values. There were modest increases in the aortic svstolic and diastolic pressures with a widening of pulse pressu.re. Similar increases in left ventricular systolic presstsre and maximum LV dP/dt (not shown in figuire) were likewise observed. The sinus rate, A-H and l--V intervals remained essentially unchanged. The onset of action of X-537A was rapid (2-5 min), with a smooth conitinutlotus progression until maximal response was attained in 10-15minutes, which persisted for about an houir then graduallv subsided over the next 11/2 hiours uintil the pretreatment control valoes were re-established.
With a constant paced ventricuilar rate, a large dose of propranolol (2 mg/kg) partially blocked the inotropic effects of X-537A. There was a 20% suppressioii of the LAV dP/clt max compared to the animals that were niot pretreated with propranolol. This dose of propranolol blocke(1 80-100Cc of the response to a 0.1 gg/kg intravenious dose of isoproterenol injected over a one minute period. However, a much greater inerease in mearn aortic pressuire was ol)served in propranolol-treate(l animals than those which did not receive propranolol, suggestive of an a-adrenergic component to the action of X-537A on the arterial vessels.
The sigrnificant suippression of lIV dP/dt max in propranolol treated animals suggests 3-adrenergic type effects of X-537A on the heart. Discussion The most striking effect of X-537A appears to be the increase in cardiac contractility, as measured at comparable heart rates by max IV dP/dt, IVST and dT/dt. The definitive mechanism or mechanisms hy which X-537A evokes this effect is not yet clear, but it is very likely to involve its interaction with inorganic cations as well as with catecholamines.
TFhe constancy of heart rate within the dose range of 0. 1-1.0 mg/kg is noteworthy and could be a compernsatory interplay of the positive chronotropic effect of X-537A, as has been observed in isolated heart preparation,5' 6 and the bradycardia effects of elevated arterial pressure mediated through the baroreceptor reflex. Evidently, at higher doses of X-537A the positive cihroriotropy predominates.
The significant but not complete suppression of the positive inotropic effects of X-537A by propranolol indicates that it probably stimulates the 3-receptors of the myocardium, while the accompanying enhancement in mean aortic pressure at a constant paced rate is indicative of a-receptor mediation in the arteries as well. It thu.s appears likely that the hemodynamic effects of X-537A are mediated at least in part by the release of mixed catecholamines, with or without an increase in their synthesis by removal of feedback inhiibition control.
The ability of X-537A to complex and transport monovalent and divalent cations had been clearly demonstrated in bulk phase and artificial membrane SVsteMS.5 6. 8, 16 It has also been shown that X-537A promotes a very rapid release of Ca++ from Ca++ loacled vesicles prepared from sarcoplasmic retic1uilm of the heart and skeletal muscles.'6 17 Since ioriophores are uisually able to translocate across biological membranes those cationic species which thev complex and transport in model systems, it seems logical to specuilate that X-537A couild make extracelltular Ca++ available to the contractile proteins of the myocardiuim even though it has not yet been specifically demonstrated that it does render the sarcolemma mnore permeable to Ca`.
It has been proposed that Cla-+ plays a rather general role in dischargirng the contents of secretory grantules including neurotransmitters"' and other horrnoies, possibly by a general stimulation of exocytosis. l9Lonophores have already been demonstrated to promote a Ca++ mediated release of acetylcholine from presynaptic neurosecretory granulles20 and the release of histamine from the mast celL`2 Irn analogous fashion X-537A may release catecholaminies from neeurosecretory granules as well as the adrenal, partially by directly rendering vesicuilar membranes permeable to catecholamines 107, 5 and partially by indirectly stimulating Ca++-mediated exocvtosis. X-537A has the capacity to stimulate a vide variety of exocytotic processes leading to the release of a complicated spectrum of hormones which could modify the pharmacological effects of the ionophore. The striking cardiovascular effects of X-537A suggests it will find therapeutic applications for treating myocardial decompensation and clinical shock of various etiologies. It parallels exogenous catecholamines in producing hemodynamically significant increases in cardiac contractility and arterial pressure. Mean arterial pressure is elevated by X-537A and the pulse pressure is widened. Total peripheral resistance is decreased. Its onset of action is slightly slower than catecholamines but its duration of action is considerably longer. It is not unlike digitalis in its significant positive inotropic action but it has a faster onset, and an earlier and shorter peak of action. A careful comparative study of effects of X-537A and digitalis preparations is presently underway.
The distinctive cardiovascular effects of X-537A and probable mechanisms of its action justify considering it as the prototype of a new class of inotropic agent. Various derivatives of X-537A might be expected to exhibit a wide spectrum of activity and duration of action. The acetyl and bromo derivatives are already known to have hemodynamic effects similar to the parent X-537A. Based on the large body of information available about the molecular properties of ionophores'-6 the hemodynamic effects of X-537A and its congeners may arise from a multiplicity of transport capabilities: (1) increase of muscular contractility by transporting Ca+ + across membranes directly or indirectly affecting its availability to the contractile elements, (2) release and/or increased synthesis of neurotransmitter, i.e., catecholamines and acetylcholine, (3) alteration of membrane potentials by translocation of Na+ and K+ across membranes, and (4) release of other hormones, i.e., glucagon and histamine. Current work is being directed toward evaluating the contributions of these transport properties to the observed pharmacological activity of X-537A. Although such hypotheses provide interesting mechanisms for the action of X-537A, more investigations in other directions are clearly required.
The capacity of X-537A to perturb membrane systems has already provided a new tool for experimentallv probing the complex factors influencing myocardial contractility via excitation-contraction coupling. The therapeutic potential of X-537A for the treatment of circulatory collapse and myocardial decompensation, as supported by the present studies, may represent a highly practical extension of the earlier more basic observations. Lastly, these studies suggest a new general therapeutic concept, namely the controlled alteration of membrane function by the systemic administration of permeability inducing agents, i.e., ionophores, for the pharmacological treatment of pathological conditions.
